Wall Street Says These 2 Stocks May Double. Should You Buy Them?
One of the exciting parts of investing is identifying companies that will offer us the next big thing. This could be a game-changing drug or an exciting technology that may transform healthcare. And two companies Wall Street is bullish on have that potential.
Intellia Therapeutics (NASDAQ: NTLA) works in the up-and-coming area of gene editing. Invitae (NYSE: NVTA) specializes in genetic testing. Both stocks have declined over the past year. But Wall Street forecasts that these innovative companies will see their shares double in the coming 12 months. Does this mean it's time to buy? Let's find out.
Intellia doesn't yet have commercialized products but generates some revenue each quarter through collaborations. The company works on various CRISPR gene editing programs with big biotech partner Regeneron. To tackle genetic diseases, Intellia uses a lipid-nanoparticle delivery system to knock out faulty genes -- and trigger repairs.
Source Fool.com
Intellia Therapeutics Inc Stock
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 60 € there is potential for a 192.11% increase which would mean more than doubling the current price of 20.54 € for Intellia Therapeutics Inc.
